Clinical Trial Update: A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on TQ-B3525 tablets combined with fulvestrant for HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• TQ-B3525

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN